Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Brief Summary: REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Biological: Convalescent plasma | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Convalescent plasma; Assigned to Arm(s): Experimental group
B: Arm Label: pathogen reduced SARS-CoV-2 convalescent plasma; Type: EXPERIMENTAL; Interventions: Biological: pathogen reduced SARS-CoV-2 convalescent plasma | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: pathogen reduced SARS-CoV-2 convalescent plasma; Assigned to Arm(s): pathogen reduced SARS-CoV-2 convalescent plasma | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Antibiotic Domain; Type: OTHER; Interventions: Drug: Ceftriaxone, Drug: Moxifloxacin or Levofloxacin, Drug: Piperacillin-tazobactam, Drug: Ceftaroline, Drug: Amoxicillin-clavulanate | Arm Label: Macrolide Duration Domain; Type: OTHER; Interventions: Drug: Standard course macrolide, Drug: Extended course macrolide | Arm Label: Corticosteroid Domain; Type: OTHER; Interventions: Other: No systemic corticosteroid, Drug: Fixed-duration Hydrocortisone, Drug: Shock-dependent hydrocortisone, Drug: Fixed-duration higher dose Hydrocortisone, Drug: Fixed-duration dexamethasone | Arm Label: Influenza Antiviral Domain; Type: OTHER; Interventions: Other: No antiviral agent for influenza, Drug: Five-days oseltamivir, Drug: Ten-days oseltamivir, Drug: Baloxavir Marboxil, Drug: Five-days oseltamivir + baloxavir marboxil, Drug: Ten-days oseltamivir + baloxavir marboxil | Arm Label: COVID-19 Antiviral Domain; Type: OTHER; Interventions: Other: No antiviral agent for COVID-19, Drug: Lopinavir / Ritonavir, Drug: Hydroxychloroquine, Drug: Hydroxychloroquine + lopinavir/ritonavir, Drug: Ivermectin | Arm Label: COVID-19 Immune Modulation Domain; Type: OTHER; Interventions: Other: No immune modulation for COVID-19, Drug: Interferon beta-1a, Drug: Anakinra, Drug: Tocilizumab, Drug: Sarilumab | Arm Label: Anticoagulation Domain; Type: OTHER; Interventions: Drug: Local standard venous thromboprophylaxis, Drug: Therapeutic dose anticoagulation, Drug: Conventional low dose thromboprophylaxis, Drug: Intermediate dose thromboprophylaxis, Drug: Continuation of therapeutic dose anticoagulation | Arm Label: Immunoglobulin Domain; Type: OTHER; Interventions: Other: No immunoglobulin, Biological: Convalescent plasma, Biological: Delayed administration of convalescent plasma | Arm Label: Vitamin C Domain; Type: OTHER; Interventions: Other: No vitamin C, Drug: Vitamin C | Arm Label: Simvastatin Domain; Type: OTHER; Interventions: Other: No simvastatin, Drug: Simvastatin | Arm Label: Antiplatelet Domain; Type: OTHER; Interventions: Other: No antiplatelet, Drug: Aspirin, Drug: P2Y12 inhibitor | Arm Label: Mechanical Ventilation Domain; Type: OTHER; Interventions: Procedure: Clinician-preferred mechanical ventilation strategy, Procedure: Protocolised mechanical ventilation strategy | Arm Label: COVID-19 Immune Modulation (2) Domain; Type: OTHER; Interventions: Other: No immune modulation for COVID-19, Drug: Eritoran, Drug: Apremilast | Arm Label: ACE2 RAS Domain; Type: OTHER; Interventions: Other: No renin-angiotensin system inhibitor, Drug: Angiotensin converting enzyme inhibitor, Drug: Angiotensin Receptor Blockers, Drug: ARB + DMX-200 | Arm Label: Cysteamine Domain; Type: OTHER; Interventions: Other: No cysteamine, Drug: Cysteamine | Arm Label: Endothelial Domain; Type: OTHER; Interventions: Other: No endothelial modulator, Drug: Imatinib | Arm Label: Influenza Immune Modulation; Type: OTHER; Interventions: Other: No Immune Modulator for Influenza, Drug: Tocilizumab, Drug: Baricitinib | Arm Label: COVID-19 Antiviral (II) Domain; Type: OTHER; Interventions: Other: No antiviral agent for COVID-19, Drug: Nirmatrelvir/ritonavir, Drug: Remdesivir, Drug: Nirmatrelvir/ritonavir + remdesivir | Intervention Type: DRUG; Name: Ceftriaxone; Assigned to Arm(s): Antibiotic Domain | Intervention Type: DRUG; Name: Moxifloxacin or Levofloxacin; Assigned to Arm(s): Antibiotic Domain | Intervention Type: DRUG; Name: Piperacillin-tazobactam; Assigned to Arm(s): Antibiotic Domain | Intervention Type: DRUG; Name: Ceftaroline; Assigned to Arm(s): Antibiotic Domain | Intervention Type: DRUG; Name: Amoxicillin-clavulanate; Assigned to Arm(s): Antibiotic Domain | Intervention Type: DRUG; Name: Standard course macrolide; Assigned to Arm(s): Macrolide Duration Domain | Intervention Type: DRUG; Name: Extended course macrolide; Assigned to Arm(s): Macrolide Duration Domain | Intervention Type: OTHER; Name: No systemic corticosteroid; Assigned to Arm(s): Corticosteroid Domain | Intervention Type: DRUG; Name: Fixed-duration Hydrocortisone; Assigned to Arm(s): Corticosteroid Domain | Intervention Type: DRUG; Name: Shock-dependent hydrocortisone; Assigned to Arm(s): Corticosteroid Domain | Intervention Type: DRUG; Name: Fixed-duration higher dose Hydrocortisone; Assigned to Arm(s): Corticosteroid Domain | Intervention Type: OTHER; Name: No antiviral agent for influenza; Assigned to Arm(s): Influenza Antiviral Domain | Intervention Type: DRUG; Name: Five-days oseltamivir; Assigned to Arm(s): Influenza Antiviral Domain | Intervention Type: DRUG; Name: Ten-days oseltamivir; Assigned to Arm(s): Influenza Antiviral Domain | Intervention Type: OTHER; Name: No antiviral agent for COVID-19; Assigned to Arm(s): COVID-19 Antiviral Domain | Intervention Type: DRUG; Name: Lopinavir / Ritonavir; Assigned to Arm(s): COVID-19 Antiviral Domain | Intervention Type: DRUG; Name: Hydroxychloroquine; Assigned to Arm(s): COVID-19 Antiviral Domain | Intervention Type: DRUG; Name: Hydroxychloroquine + lopinavir/ritonavir; Assigned to Arm(s): COVID-19 Antiviral Domain | Intervention Type: DRUG; Name: Ivermectin; Assigned to Arm(s): COVID-19 Antiviral Domain | Intervention Type: OTHER; Name: No immune modulation for COVID-19; Assigned to Arm(s): COVID-19 Immune Modulation (2) Domain, COVID-19 Immune Modulation Domain | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): COVID-19 Immune Modulation Domain | Intervention Type: DRUG; Name: Anakinra; Assigned to Arm(s): COVID-19 Immune Modulation Domain | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): COVID-19 Immune Modulation Domain | Intervention Type: DRUG; Name: Sarilumab; Assigned to Arm(s): COVID-19 Immune Modulation Domain | Intervention Type: DRUG; Name: Local standard venous thromboprophylaxis; Assigned to Arm(s): Anticoagulation Domain | Intervention Type: DRUG; Name: Therapeutic dose anticoagulation; Assigned to Arm(s): Anticoagulation Domain | Intervention Type: DRUG; Name: Conventional low dose thromboprophylaxis; Assigned to Arm(s): Anticoagulation Domain | Intervention Type: DRUG; Name: Intermediate dose thromboprophylaxis; Assigned to Arm(s): Anticoagulation Domain | Intervention Type: DRUG; Name: Continuation of therapeutic dose anticoagulation; Assigned to Arm(s): Anticoagulation Domain | Intervention Type: OTHER; Name: No immunoglobulin; Assigned to Arm(s): Immunoglobulin Domain | Intervention Type: BIOLOGICAL; Name: Convalescent plasma; Assigned to Arm(s): Immunoglobulin Domain | Intervention Type: BIOLOGICAL; Name: Delayed administration of convalescent plasma; Assigned to Arm(s): Immunoglobulin Domain | Intervention Type: OTHER; Name: No vitamin C; Assigned to Arm(s): Vitamin C Domain | Intervention Type: DRUG; Name: Vitamin C; Assigned to Arm(s): Vitamin C Domain | Intervention Type: OTHER; Name: No antiplatelet; Assigned to Arm(s): Antiplatelet Domain | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Antiplatelet Domain | Intervention Type: DRUG; Name: P2Y12 inhibitor; Assigned to Arm(s): Antiplatelet Domain | Intervention Type: OTHER; Name: No simvastatin; Assigned to Arm(s): Simvastatin Domain | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Simvastatin Domain | Intervention Type: DRUG; Name: Eritoran; Assigned to Arm(s): COVID-19 Immune Modulation (2) Domain | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): COVID-19 Immune Modulation (2) Domain | Intervention Type: PROCEDURE; Name: Clinician-preferred mechanical ventilation strategy; Assigned to Arm(s): Mechanical Ventilation Domain | Intervention Type: PROCEDURE; Name: Protocolised mechanical ventilation strategy; Assigned to Arm(s): Mechanical Ventilation Domain | Intervention Type: OTHER; Name: No renin-angiotensin system inhibitor; Assigned to Arm(s): ACE2 RAS Domain | Intervention Type: DRUG; Name: Angiotensin converting enzyme inhibitor; Assigned to Arm(s): ACE2 RAS Domain | Intervention Type: DRUG; Name: Angiotensin Receptor Blockers; Assigned to Arm(s): ACE2 RAS Domain | Intervention Type: DRUG; Name: ARB + DMX-200; Assigned to Arm(s): ACE2 RAS Domain | Intervention Type: OTHER; Name: No cysteamine; Assigned to Arm(s): Cysteamine Domain | Intervention Type: DRUG; Name: Cysteamine; Assigned to Arm(s): Cysteamine Domain | Intervention Type: DRUG; Name: Fixed-duration dexamethasone; Assigned to Arm(s): Corticosteroid Domain | Intervention Type: DRUG; Name: Baloxavir Marboxil; Assigned to Arm(s): Influenza Antiviral Domain | Intervention Type: DRUG; Name: Five-days oseltamivir + baloxavir marboxil; Assigned to Arm(s): Influenza Antiviral Domain | Intervention Type: DRUG; Name: Ten-days oseltamivir + baloxavir marboxil; Assigned to Arm(s): Influenza Antiviral Domain | Intervention Type: OTHER; Name: No endothelial modulator; Assigned to Arm(s): Endothelial Domain | Intervention Type: DRUG; Name: Imatinib; Assigned to Arm(s): Endothelial Domain | Intervention Type: OTHER; Name: No Immune Modulator for Influenza; Assigned to Arm(s): Influenza Immune Modulation | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Influenza Immune Modulation | Intervention Type: DRUG; Name: Baricitinib; Assigned to Arm(s): Influenza Immune Modulation | Intervention Type: OTHER; Name: No antiviral agent for COVID-19; Assigned to Arm(s): COVID-19 Antiviral (II) Domain | Intervention Type: DRUG; Name: Nirmatrelvir/ritonavir; Assigned to Arm(s): COVID-19 Antiviral (II) Domain | Intervention Type: DRUG; Name: Remdesivir; Assigned to Arm(s): COVID-19 Antiviral (II) Domain | Intervention Type: DRUG; Name: Nirmatrelvir/ritonavir + remdesivir; Assigned to Arm(s): COVID-19 Antiviral (II) Domain
D: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Routine care for COVID-19 patients | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2 | Intervention Type: OTHER; Name: plasma therapy using convalescent plasma with antibody against SARS-CoV-2; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Routine care for COVID-19 patients; Assigned to Arm(s): Control group

Answer: C